TScan Therapeutics

TCRX on Nasdaq. Market value $57m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 60 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • at least 13.1%−1.9 pts
    (filed with 1 related holder)
    Since 30 June 2026
  • BVF PARTNERS L P/IL
    Passive investor
    at least 10.0%0.0 pts
    (filed with 9 related holders)
    Since 30 June 2026
  • Adage Capital Management, L.P.
    Passive investor
    at least 7.1%
    (filed with 1 related holder)
    Since 31 December 2024
  • K2 HealthVentures Equity Trust LLC
    Passive investor
    at least 6.9%
    (filed with 2 related holders)
    Since 31 December 2024
  • Readout Capital, LP
    Passive investor
    at least 5.4%
    (filed with 2 related holders)
    Since 21 September 2026
  • Adage Capital Management, L.P.
    Passive investor
    at least 2.5%−4.6 pts
    (filed with 2 related holders)
    Since 30 June 2025
  • BlackRock, Inc.
    Passive investor
    Sold down below 5%
    Since 30 June 2025
  • EcoR1 Capital, LLC
    Passive investor
    Sold down below 5%
    Since 31 March 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in TScan Therapeutics’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 4 Mar 2026, plus the 10-Q filed 12 Nov 2026 and 11 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “• We have identified conditions that raise substantial doubt about our ability to continue as a going concern.”

    From the 10-Q filed 12 November 2026, Part I. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

A serious warning sign just appeared in its filings. Read what it says before you buy.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.